Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DX-201
- Development stage
- Preclinical
- Lead developer
- Delonix Bioworks
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
01
Overview
DX-201 is a genetically detoxified pertussis toxin bacterial vaccine being developed by Delonix Bioworks for the prevention of whooping cough (*Bordetella pertussis*). Utilizing the proprietary BioDVax platform, DX-201 is engineered to express a non-toxic version of the pertussis toxin within a bacterial vector. This approach aims to induce a robust and protective immune response while minimizing the toxicity and side effects associated with traditional pertussis vaccines. DX-201 is currently in the lead optimization stage of preclinical development.
- Other names
- BioDVaxgenetically detoxified pertussis toxin vaccinegdPT vaccine
Beyond the preview
Go deeper on DX-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DX-201.